Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869984 | 0.75 | LMNA (0.44) | ERN1TYRALDH1A1 | |
| SCHEMBL1670597 | 0.69 | ERN1 (0.52) | ERN1CYP2A6PTGDR2TYRPTPN1 | |
| SCHEMBL18794537 | 0.68 | ERN1 (0.50) | ERN1CYP2A6PTGDR2TYRPTPN1 | |
| SCHEMBL3040456 | 0.67 | ERN1 (0.64) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL144351 | 0.66 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL31401340 | 0.66 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL137546 | 0.66 | ERN1 (0.57) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL15264345 | 0.66 | ERN1 (0.47) | ERN1CYP2A6PTGDR2TYRPTPN1 | |
| SCHEMBL21558279 | 0.66 | ERN1 (0.47) | ERN1CYP2A6PTGDR2TYRPTPN1 | |
| SCHEMBL177142 | 0.66 | ALDH1A1 (0.52) | ERN1CYP2A6PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567028-B1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | MEDSHINE DISCOVERY INC (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| EP-3567028-A1 | BIPHENYL COMPOUND AS CCR2/CCR5 RECEPTOR ANTAGONIST | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | ERN1 4488/4885CYP2A6 308/4885PTGDR2 366/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | ERN1 4488/4885CYP2A6 308/4885PTGDR2 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.